This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by McCrae, K. Search for Related Content PubMed PubMed Citation Articles by McCrae, K. Social Bookmarking                         What's this?

Antiphospholipid antibody associated thrombosis: A consensus for treatment?

Department of Medicine and the Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, USA

The results of several studies have demonstrated that antiphospholipid antibodies (APLA) are associated with an increased risk of both venous and arterial thrombosis. Additional work has suggested that patients with antiphospholipid antibody-associated thrombosis are at a markedly increased risk for recurrent thrombotic disease, and several investigators have suggested that such patients should receive high-intensity anticoagulant therapy for an indefinite period of time for prophylaxis of recurrent thrombotic events. However, the majority of these studies are retrospective and include highly-selected patient populations, and the potential morbidity of long-term, intensive warfarin therapy has not been fully considered. In this article, studies concerning the incidence and prevention of recurrent thrombosis in patients with antiphospholipid antibodies are reviewed. I will also present the results of a survey in which opinions concerning selected issues in prophylactic anticoagulant therapy of patients with antiphospholipid antibody-associated venous thrombosis were obtained from prominent clinicians with expertise in this area. The results of the survey demonstrate that opinions concerning this issue vary widely, and emphasize the need for additional prospective studies examining the utility of specific anticoagulant regimens in the prophylaxis of recurrent thromboembolism in patients with antiphospholipid antibodies.

Key Words: antiphospholipid antibodies • lupus anticoagulant • anticardiolipin antibodies • thrombo sis • warfarin

Lupus, Vol. 5, No. 6, 560-570 (1996)
DOI: 10.1177/096120339600500602


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. K. Srinivasan, M. R. Pittelkow, and L. T. Cooper JR Recombinant Tissue Plasminogen Activator for the Treatment of Cutaneous Infarctions in Antiphospholipid Antibody Syndrome: A Case Report Angiology, September 1, 2001; 52(9): 635 - 639. [Abstract] [PDF]

				B. G. Macik, J. H. Rand, and B. A. Konkle Thrombophilia: What's a Practitioner to Do? Hematology, January 1, 2001; 2001(1): 322 - 338. [Abstract] [Full Text] [PDF]

				D. G. Wahl, H. Bounameaux, P. de Moerloose, and F. P. Sarasin Prophylactic Antithrombotic Therapy for Patients With Systemic Lupus Erythematosus With or Without Antiphospholipid Antibodies: Do the Benefits Outweigh the Risks? A Decision Analysis Arch Intern Med, July 10, 2000; 160(13): 2042 - 2048. [Abstract] [Full Text] [PDF]

				D G Wahl, F Guillemin, E de Maistre, C Perret-Guillaume, T Lecompte, and G Thibaut Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis Lupus, January 1, 1998; 7(1): 15 - 22. [Abstract] [PDF]